
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is viewed favorably because its Dynamo platform is designed to unlock previously intractable targets, while the clinical pipeline led by zovegalisib is generating encouraging data across vascular anomalies and breast cancer. The company reported 2Q26 net loss of $0.41 per share, with R&D of $76.5M and SG&A of $14.7M, yet still ended 2Q26 with $910.9M in cash, implying an operational runway into 2029 and reducing near-term financing risk. The combination of strong efficacy signals, a 24.51% short interest, and multiple expected updates by end-2026 and in 1H27 creates a compelling setup for a meaningful re-rating if upcoming results confirm prior progress.
Bears say
Relay Therapeutics is exposed to substantial clinical risk because drug development is inherently uncertain, and its assets may fail to show sufficient efficacy or safety in current or future trials. Its prospects also depend on securing FDA and foreign regulatory approval, where any delay or failure could undermine commercialization, while the oncology field is intensely competitive against larger, better-resourced biotechnology and pharmaceutical peers. Financially, the company is likely to need additional equity financing through a secondary offering to fund development of its drug candidates, creating dilution risk for existing shareholders.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Relay Therapeutics, Inc. (RLAY) Forecast
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares